Waters Launches Charge Detection Mass Spectrometry Technology to Accelerate the Development of Next-Generation Biotherapeutics

EQS-News: Waters Corporation / Key word(s): Product Launch Waters Launches Charge Detection Mass Spectrometry Technology to Accelerate the Development of Next-Generation Biotherapeutics 13.10.2025 / 14:10 CET/CEST The issuer is solely responsible for the content of this announcement. Headlines:

• Xevo CDMS facilitates direct, accurate mass detection for the largest, most heterogeneous biomolecules.¹
• Enables accurate analysis of protein complexes, nucleic acids, and gene delivery vehicles, including distinguishing between empty, partial, full, and overfull viral vector capsids in less than 10 minutes per sample.²
• Decreases sample volumes by 100 times vs. current methods for assessing cells and nucleic acids.³

MILFORD, Mass., Oct. 13, 2025 /PRNewswire/ -- Waters Corporation (NYSE: WAT) today unveiled the Waters Xevo Charge Detection Mass Spectrometer (CDMS), delivering unmatched measurement and characterization for the broadest range of mega-mass biomolecules central to next-generation therapeutics and structural biology. With the rapid growth of cell and gene therapies, mRNA, and complex protein therapeutics, scientists face significant challenges in analyzing increasingly large and heterogeneous drug modalities – yet existing tools are limited in resolution, sensitivity, and compliance-readiness. The Xevo CDMS System addresses these gaps with direct, individual-particle mass measurement for molecules up to 150+ MDa, enabling previously unattainable analysis of protein complexes, nucleic acids, lipid nanoparticles, viral vectors, and more.

"Waters continues to make strategic investments in large molecules, recognizing that advanced tools for bioanalytical characterization play a critical role in driving therapeutic breakthroughs. Today, we are proud to introduce the first-of-its-kind Xevo Charge Detection Mass Spectrometer, enabling the precise analysis of previously unmeasurable molecules," said Udit Batra, Ph.D., President and Chief Executive Officer, Waters Corporation. "We believe the Xevo CDMS will accelerate the global development of genetic medicines and other advanced modalities by providing a greater understanding of the characteristics of large molecules earlier in development, which is crucial for making life-changing therapies more accessible to patients."